Premium
Expression of transforming growth factor‐βI in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment
Author(s) -
Lindström Pernilla,
Bergh Anders,
Holm Ingvar,
Damber JanErik
Publication year - 1996
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(199610)29:4<209::aid-pros2>3.0.co;2-6
Subject(s) - prostate , estrogen , castration , medicine , prostate cancer , endocrinology , prostate carcinoma , hormone , cancer
BACKGROUND In normal prostate, TGF‐β1 is associated to castration induced apoptosis. Combined castration and estrogen treatment, but not castration alone, induces apoptosis in the Dunning R3327 PAP adenocarcinoma. METHODS TGF‐β1 expression in rat ventral prostate (VP) and Dunning R3327‐PAP tumor was studied after castration and estrogen treatment, using competitive RT‐PCR, in situ hybridization and immunohistochemistry. RESULTS TGF‐β1 mRNA level was 6 times higher in the tumor than in the VP. Combined castration and estrogen treatment increased TGF‐β1 mRNA levels in the tumor from day 3, while castration did not. The TGF‐β1 expression was located in the epithelial cells. CONCLUSIONS The Dunning R3327 PAP tumor contains high levels of TGF‐β1, which are further increased by combined castration and estrogen treatment. However, since this increase is not apparent until day 3, TGF‐β1 probably does not contribute to the known induction of apoptosis in the tumor at day 1 after combined castration and estrogen treatment. © 1996 Wiley‐Liss, Inc.